News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eirgenix Signs Agreement With Taimed To Provide Development And Manufacturing Services For Taimed’s Second Generation anti-HIV mAb TMB-360



8/7/2014 1:53:56 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EirGenix Inc announced that it has signed the agreement with TaiMed Biologics to provide development and manufacturing services for TaiMed’s second generation anti-HIV monoclonal antibody, TMB-360. The scope of this collaboration project includes cell line development, process development and scale-up for manufacturing to provide materials for pre-clinical and clinical studies.

Compared to the first generation anti-HIV mAb, TMB-355, the new generation drug possesses significant improvements in terms of overcoming anti-drug resistance, efficiency and pharmacokinetics; with these advantages, TMB-360 will become a stronger successor to TMB-355 to benefit patients diagnosed with AIDS. By utilizing EirGenix’s development platforms and manufacturing services, it is anticipated TMB-360 will reach the market well within the expected schedule.

About EirGenix Inc.

EirGenix provides high quality, cost effective and client-oriented development and manufacturing services of biologic products for customers across the globe. It also develops its own biologic products together with partners in order to benefit the community and society as a whole. Currently, there are three products in the pipeline. EirGenix operates two manufacturing facilities: the mammalian cell production facility, consisting of two bioreactor trains (a 20/100/500L stainless steel bioreactor system and a 50/200/1000L single-use bioreactor system) and one downstream purification suite; and the microbial production pilot facility, possessing fermentation tanks with capacities up to 100L and also one downstream purification suite. The planning for a large scale mammalian cell production plant containing two 5000L reactors is well under way, with the first to come online in 2016. The company possesses extensive experience of developing and manufacturing different biologic products, e.g. monoclonal antibodies, recombinant proteins, pegylated r-proteins, and DNA plasmids.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES